HeartBeam Inc. (NASDAQ: BEAT) announced that management will attend three conferences in March 2026 to provide updates on its commercial launch and demonstrate its cardiac monitoring technology.

CEO Robert Eno and CFO Timothy Cruickshank will participate in the virtual Oppenheimer 36th Annual Healthcare MedTech & Services Conference on March 16-17, 2026. Eno will present on March 16 at 11:20 a.m. Eastern time, with the session available via webcast.

The executives will also attend the 38th Annual ROTH Conference in Dana Point, California on March 23-24, 2026. Eno will participate in a panel discussion titled "Technologies Advancing Healthy Aging" on March 23 at 5:00 p.m. Eastern time.

At ACC.26, the American College of Cardiology's annual scientific conference in New Orleans from March 28-30, 2026, HeartBeam will operate booth #209. The company plans to demonstrate its FDA-cleared HeartBeam System alongside a working prototype of its 12-lead ECG extended wear patch, which has not received FDA approval. Eno will be joined by Founder and President Dr. Branislav Vajdic and Chief Commercial Officer Bryan Humbarger.

The Santa Clara-based medical technology company received FDA clearance for its 3D ECG technology for arrhythmia assessment in December 2024 and for its 12-lead ECG synthesis software in December 2025, according to the press release statement. The company holds over 20 issued patents related to its technology.

HeartBeam's technology creates cable-free devices that collect ECG signals in three dimensions and synthesize them into a 12-lead ECG format for cardiac monitoring outside medical facilities.